Gut Liver.
2014 Jan;8(1):109-112.
Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature
- Affiliations
-
- 1Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. mjchung@yuhs.ac
- 2Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- 3Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Abstract
- Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine
- A Case of the Diarrhea-associated Hemolytic Uremic Syndrome Developing Simultaneously with an Acute Appendicitis
- A clinical aspect of the hemolytic uremic syndrome
- Case Report of Pregnancy Induced Atypical Hemolytic-uremic Syndrome
- Plasma Exchange in the Treatment of Cyclosporine Induced Hemolytic Uremic Syndrome Following Kidney Transplantaion
